Summary by Moomoo AI
SINDA BIOPHARMACEUTICAL CO., LTD. (“SINDA BIO”) RELEASED AN INSIDE STATEMENT ON FEBRUARY 6, 2024, ANNOUNCING THAT ITS FOURTH QUARTER PRODUCT REVENUE IN 2023 EXCEEDED RMB16 BILLION, AN INCREASE OF MORE THAN 65% YEAR-ON-YEAR. The company said this strong growth was driven by a further strengthening of its market leadership for products such as Dabersho® (Cindlyone Anti-Injection), as well as a diversification of its product portfolio. SindaBio continues to expand its product lines in the fields of oncology and cardiovascular, metabolism, autoimmune, ophthalmology, etc., and is steadily advancing commercialization. The Company's two innovative tumor-targeting drugs, IBI-344 and IBI-351, are eligible for priority review. Currently, Sinda Biologics has ten approved products and several new drug strains are in clinical trials at different stages. THE COMPANY EMPHASIZES THAT FINANCIAL INFORMATION NOT AUDITED OR REVIEWED BY AN EXTERNAL AUDITOR IS FOR INVESTOR REFERENCE ONLY AND IS NOT AN OFFER TO BUY OR SELL SECURITIES.